Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00655226 · ClinicalTrials.gov registry record · NA

Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients

A NA study, sponsored by Icahn School of Medicine at Mount Sinai.

Terminated
Registry status
NA
Development phase
26
Enrollment target

NCT00655226: Clinical Trial NA study, sponsored by Icahn School of Medicine at Mount Sinai.

NCT00655226 is a NA study that was terminated before completion, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 26 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00655226, a NA study, was terminated before completion, sponsored by Icahn School of Medicine at Mount Sinai.

TERMINATED
Registry status
NA
Development phase
26 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether cognitive behavioral therapy (CBT) is effective in the prevention of depression during interferon and ribavirin treatment for hepatitis C infection.

Interventions

  • BEHAVIORAL Hepatitis C educational support groups
  • BEHAVIORAL Cognitive Behavioral Therapy skills based group sessions

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2008-03
Est. Completion 2010-05
Phase NA

Why NCT00655226 stopped before completion

NCT00655226 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which Hepatitis C educational support groups is the first listed.

NCT00655226 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00655226 about?

NCT00655226 is a clinical study titled "Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients". The purpose of this study is to determine whether cognitive behavioral therapy (CBT) is effective in the prevention of depression during interferon and ribavirin treatment for hepatitis C infection.

What is the current status of trial NCT00655226?

This trial is currently terminated. It is a NA study. The enrollment target is 26 participants. The study started on 2008-03. Estimated completion is 2010-05.

What interventions are being tested in trial NCT00655226?

The interventions under investigation include: Hepatitis C educational support groups (BEHAVIORAL), Cognitive Behavioral Therapy skills based group sessions (BEHAVIORAL).

Who is sponsoring clinical trial NCT00655226?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00655226's enrollment target sits among peer trials

26 1710th of 2000 higher than 289 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02646475 · 26 participants · Phase 1

    Metabolic Effects of Angiotensin-(1-7)

  • NCT03603223 · 26 participants · Phase 2

    Pembrolizumab in Treating Participants With Leukoplakia

  • NCT04063592 · 26 participants · NA

    AMI Construction in Lower Extremity Residual Limbs

  • NCT04906460 · 26 participants · Phase 1

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00655226, the US trial registry maintained by the National Library of Medicine. NCT00655226 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.